Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 162

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 162
---
 34,216 |     |                     | — |

Change in Control Payments In connection with the Arrangement, Mr. Forte will be eligible to receive a one-timecash bonus of $750,000 (a “ CIC Bonus”). Mr. Forte’s CIC Bonus will be paid in a lump sum, immediately prior to the Effective Time, subject to applicable withholdings. The table below sets forth the estimated value of the CIC Bonus.

| Name        |     | CIC Bonus ($) |         |
|:------------|:----|:--------------|--------:|
| Steve Forte |     | $             | 750,000 |

Potential Severance Payments and Benefits Other than with respect to Mr. Segal and Dr. Koehler, each of our executive officers is eligible to receive benefits under an individual agreement with the Company. The severance provisions of each executive officers’ employment agreement are described in the paragraphs below. As noted above, Mr. Segal and Dr. Koehler each departed from the Company earlier in 2025 and entered into separation agreements with the Company in connection with their departures. As such, neither of Mr. Segal nor Dr. Koehler are eligible to receive additional severance. Pursuant to an Employment Agreement dated June 12, 2020, as amended on July 13, 2023 and June 13, 2025, between Dr. Zinda and the Company, in the event Dr. Zinda is terminated without “cause” or resigns for “good reason” (each, as defined in the employment agreements), Dr. Zinda is entitled to (i) an amount equal to nine months of Dr. Zinda’s base salary in effect as of the date of his termination, payable in equal monthly installments; (ii) COBRA premiums equal to the cost of coverage the Company was paying as of the date of termination for a period of up to 12 months; (iii) an additional nine months of vesting and an extended post termination period of up to nine months (other than with respect to incentive stock options) following Dr. Zinda’s termination for all stock options held by Dr. Zinda that are subject to a time-based vesting schedule; and (iv) a prorated annual bonus paid at the target bonus level for the year in which Dr. Zinda’s employment is terminated. In the event Dr. Zinda is terminated without “cause” or resigns for “good reason” within 90 days prior